Schonfeld Strategic Advisors LLC Crinetics Pharmaceuticals, Inc. Transaction History
Schonfeld Strategic Advisors LLC
- $15.4 Billion
- Q4 2024
A detailed history of Schonfeld Strategic Advisors LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 445,946 shares of CRNX stock, worth $16 Million. This represents 0.15% of its overall portfolio holdings.
Number of Shares
445,946
Previous 490,725
9.13%
Holding current value
$16 Million
Previous $25.1 Million
9.04%
% of portfolio
0.15%
Previous 0.18%
Shares
11 transactions
Others Institutions Holding CRNX
# of Institutions
255Shares Held
89.5MCall Options Held
26.1KPut Options Held
11.8K-
Vanguard Group Inc Valley Forge, PA9.09MShares$325 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA6.95MShares$249 Million0.07% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$223 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.14MShares$220 Million3.06% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.41MShares$194 Million0.03% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.92B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...